Levit R, de Giori G Savoy, de Moreno de LeBlanc A, LeBlanc J G
1 Centro de Referencia para Lactobacilos (CERELA-CONICET), Chacabuco 145, T4000ILC San Miguel de Tucumán, Tucumán, Argentina.
2 Cátedra de Microbiología Superior, Facultad de Bioquímica, Química y Farmacia, Universidad Nacional de Tucumán, Calle Batalla de Ayacucho 471, 4000 San Miguel de Tucumán, Tucumán, Argentina.
Benef Microbes. 2017 Feb 7;8(1):65-72. doi: 10.3920/BM2016.0063. Epub 2016 Nov 22.
Inflammatory bowel diseases (IBD) are idiopathic diseases of the gastrointestinal tract characterised by recurrent inflammation that require lifelong treatments. It has been shown that certain strains of lactic acid bacteria (LAB) can produce specific health-promoting compounds in foods or in the gastrointestinal tract that can in turn prevent and/or treat IBD. This study was designed to evaluate the possible therapeutic potential of soymilk fermented by the riboflavin-producing strain Lactobacillus plantarum CRL 2130 in a trinitrobenzene sulfonic induced colitis mouse model. Mice that received soymilk fermented by L. plantarum CRL 2130 showed a decrease in weight loss, lower damage scores in their large intestines, lower microbial translocation to liver and decreased cytokines levels in their intestinal fluids compared to animals that received unfermented soymilk or soymilk fermented by a non-riboflavin-producing L. plantarum strain. This is the first report that demonstrates that a riboflavin-producing LAB was able to prevent experimental colitis in a murine model.
炎症性肠病（IBD）是胃肠道的特发性疾病，其特征为反复炎症，需要终身治疗。研究表明，某些乳酸菌（LAB）菌株可在食物或胃肠道中产生特定的促进健康的化合物，进而预防和/或治疗IBD。本研究旨在评估由产核黄素的植物乳杆菌CRL 2130发酵的豆浆在三硝基苯磺酸诱导的结肠炎小鼠模型中的潜在治疗潜力。与接受未发酵豆浆或由不产核黄素的植物乳杆菌菌株发酵的豆浆的动物相比，接受植物乳杆菌CRL 2130发酵豆浆的小鼠体重减轻减少，大肠损伤评分降低，微生物向肝脏的易位减少，肠液中细胞因子水平降低。这是第一份证明产核黄素的LAB能够在小鼠模型中预防实验性结肠炎的报告。
